Antituberculosis (anti-TB) treatment may be affected by both diabetes and hypoglycemic agents in patients with these 2 comorbidities. However, data supporting this conclusion relate only to standard anti-TB therapies. Sirturo® (bedaquiline) and Deltyba® (delamanid), novel drugs for multidrug-resistant tuberculosis (MDR-TB), are recommended for diabetes patients when another effective treatment ...

background and objectives this study was undertaken to evaluate the effect of the cultivated satureja khuzestanica essential oil (skeo) on activity and gene expression of hepatic gk in normal and diabetic rats.   methods biochemical parameters such as glucose, insulin, and hba1c plasma levels and oral glucose tolerance test were all analyzed. the cultivated skeo was orally administered at diffe...

Background: New noninsulin hypoglycemic agents, the incretin and amylin groups, are available to treat patients with type 2 diabetes and inadequate glucose control with the regular routinely used agents, namely metformin or sulfonylurea. Incretin therapies are based on the release of intestinal peptides (glucagon-like peptide 1) in the presence of glucose in the gut which stimulates insulin sec...

INTRODUCTION Adherence to oral hypoglycemic agents is essential to reducing the poor health outcomes of populations at high risk for developing diabetes and its chronic complications. The goal of this study was to identify characteristics of patients in Hawaii least likely to adhere to oral hypoglycemic agents. METHODS This retrospective administrative data analysis included prescription refi...